ASCO GU Symposium Announces New Findings on Tumor Reduction and Survival Outcomes in Advanced Renal Cell Carcinoma
The latest analysis, presented Feb. 13-14 at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2025), further solidifies the effectiveness of the lenvatinib (Lenvima) and pembrolizumab (Keytruda) combination in treating this aggressive form of kidney cancer. Hutson played a key role in the study and provided insights into the impact of these findings.
“This analysis reinforces that greater tumor shrinkage correlates with improved survival outcomes,” Hutson said. “We now have compelling evidence that reducing overall tumor burden not only extends survival but also enhances the effectiveness of subsequent treatments, setting patients up for better long-term prognoses.”
The study, which initially led to the FDA approval of lenvatinib plus pembrolizumab for advanced renal cell carcinoma in 2021, continues to provide valuable insights into treatment strategies. The new findings demonstrate that patients with greater reductions in total tumor size at disease progression had significantly longer median survival rates. Additionally, data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) show that patients receiving the combination therapy were more likely to maintain or improve their IMDC risk scores, further supporting the regimen’s impact on long-term survival.
“These findings emphasize the importance of aggressive tumor reduction in the fight against renal cell carcinoma,” Hutson added. “The data suggest that this combination therapy offers the best outcomes among currently available treatments, making it a strong contender for first-line treatment in advanced renal cell carcinoma.”
TTUHSC and UMC Health System remain committed to advancing cancer treatment and improving patient outcomes through innovative research and clinical excellence.
About Texas Tech University Health Sciences Center
TTUHSC is a medical education, research and patient care leader dedicated to improving health outcomes across Texas and beyond.
About UMC Health System
UMC Health System is a nationally recognized academic medical center committed to delivering advanced patient care, innovative research and comprehensive cancer treatment.
Related Stories
Student Research Shows Positive Outcomes from Summer Research Program
Medical student involvement in research is growing, encouraging medical schools to develop programs that support student research plus faculty time for research and mentorship. The Medical Student Summer Research Program (MSSRP) at TTUHSC provides these opportunities, and new research shows positive outcomes.
‘Tropical Neglected Disease’ Not Forgotten by TTUHSC Researcher
Afzal Siddiqui, Ph.D., director of the TTUHSC Center for Tropical Medicine and Infectious Diseases, developed SchistoShield®, a vaccine to treat schistosomiasis, as a humanitarian effort, rather than making it for profit.
Study Finds Variety, Intensity of Exercise Lower Odds of Depressive Symptoms
The study, conducted by a team at the Kenneth H. Cooper Institute at Texas Tech University Health Sciences Center (TTUHSC), analyzed data from more than 38,000 adult participants in the Cooper Center Longitudinal Study to better understand how different characteristics of physical activity relate to depressive symptoms measured by the Center for Epidemiologic Studies Depression Scale (CES-D), a widely used screening tool.
Recent Stories
Student Research Shows Positive Outcomes from Summer Research Program
Medical student involvement in research is growing, encouraging medical schools to develop programs that support student research plus faculty time for research and mentorship. The Medical Student Summer Research Program (MSSRP) at TTUHSC provides these opportunities, and new research shows positive outcomes.
Stay Safe: Preventing Summertime Dehydration
As the summer heat continues to intensify, so does the risk for dehydration. Prioritizing hydration this summer can protect you and your loved ones from potentially life-threatening complications.
Julia Jones Matthews School of Population and Public Health Offers New Graduate Certificate in Epidemiology
The TTUHSC Julia Jones Matthews School of Population and Public Health is launching a new MPH concentration in Epidemiology and a Graduate Certificate in Epidemiology.